Ovarian Cancer Market Positioned to Grow with a CAGR of 7.4% Through 2034

The Ovarian Cancer market was valued at approximately USD 3 billion in the 7MM in 2025 and is projected to grow at a robust CAGR of 7.4% during the forecast period (2020–2034). DelveInsight's comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Ovarian Cancer landscape.

By analyzing historical data, current market dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The ovarian cancer market is increasingly guided by biomarker-driven strategies and targeted therapies. PARP inhibitors represent a highly lucrative segment, highlighted by breakthrough treatments like olaparib, niraparib, and rucaparib for BRCA-mutated ovarian cancer. The folate receptor alpha-targeted antibody-drug conjugate mirvetuximab soravtansine-gynx has emerged as the first approved therapy specifically for FRα-positive platinum-resistant ovarian cancer, demonstrating response rates exceeding 30% in clinical trials.

Ovarian cancer is the seventh most common cancer and the eighth leading cause of death in women worldwide. The United States accounts for the highest number of incident cases of High and Low-grade serous ovarian Cancer. In the 7MM, there were nearly 38K ovarian cancer cases in 2024. Age plays a significant role in ovarian cancer prevalence, with individuals aged 65 and older being disproportionately affected. More than 48% of all ovarian cancer cases occur in women aged 65 and above, with the median age at diagnosis being 63 years.

Epithelial ovarian cancer accounts for approximately 90% of all ovarian cancer cases, with high-grade serous ovarian cancer representing the most common subtype. About 80% of high-grade serous ovarian cancer patients have tumors that overexpress folate receptor alpha, making them eligible for FRα-targeted therapies. BRCA1/2 mutations are detected in approximately 15-20% of ovarian cancer patients, with these patients demonstrating exceptional response to PARP inhibitor therapies.

DelveInsight's report, "Ovarian Cancer Market Insights, Epidemiology, and Market Forecast-2034" provides a comprehensive analysis of the Ovarian Cancer landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines the ovarian cancer market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To Know in detail about the Ovarian Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here: Ovarian Cancer Market Forecast

Some of the key facts of the Ovarian Cancer Market Report

• Key Ovarian Cancer Companies: AstraZeneca, Merck, GSK, AbbVie (ImmunoGen), Bristol-Myers Squibb, Roche/Genentech, Clovis Oncology, Genmab, Eli Lilly (Mablink), Verastem, Bio-Thera Solutions, Allarity Therapeutics, OncoQuest Pharmaceuticals, and others
• Key Ovarian Cancer Therapies: Olaparib (Lynparza), Niraparib (Zejula), Rucaparib (Rubraca), Mirvetuximab soravtansine-gynx (Elahere), Bevacizumab (Avastin), Pembrolizumab (Keytruda), Dostarlimab-gxly (Jemperli), Avutometinib + Defactinib (Avmapki Fakzynja), Rinatabart sesutecan, LY4170156, Torvutatug samrotecan (AZD5335), BAT8006, Stenoparib, Oregovomab, and others
• The Ovarian Cancer market is expected to surge due to the launch of various multiple-stage Ovarian Cancer pipeline products, significantly revolutionizing the ovarian Cancer market dynamics.

Ovarian Cancer Overview

Ovarian Cancer is one of the most lethal gynecological malignancies affecting women worldwide, accounting for approximately 3.7% of all cancer cases and 4.7% of cancer deaths globally. It originates in the ovaries and includes several subtypes, such as epithelial ovarian cancer, germ cell tumors, and stromal cell tumors, with epithelial ovarian cancer being the most prevalent.

The disease is often diagnosed at advanced stages due to its subtle and nonspecific symptoms, including abdominal discomfort, bloating, pelvic pain, changes in bowel or urinary habits, and feeling full quickly. Risk factors include advancing age, family history of breast or ovarian cancer, BRCA1/2 gene mutations, nulliparity, endometriosis, and hormone replacement therapy. Early detection remains challenging due to the absence of effective screening programs for the general population, making biomarker testing and molecular diagnostics increasingly important in disease management.

Get a Free sample for the Ovarian Cancer Market Report

Key Trends in Ovarian Cancer Therapeutics Market

• Rising Adoption of PARP Inhibitors: Increasing use of olaparib, niraparib, and rucaparib for BRCA-mutated and HRD-positive ovarian cancer as maintenance therapy following platinum-based chemotherapy, demonstrating significant progression-free survival benefits.
• Emergence of Antibody-Drug Conjugates: Growing development of FRα-targeted ADCs including mirvetuximab soravtansine-gynx (Elahere), rinatabart sesutecan, LY4170156, and torvutatug samrotecan showing objective response rates between 40-60% in platinum-resistant disease.
• Immunotherapy Integration: Expanding investigation of immune checkpoint inhibitors such as pembrolizumab, nivolumab, and dostarlimab in combination with chemotherapy and other targeted agents, though single-agent response rates remain modest at 10-15%.
• Precision Medicine & Biomarker Testing: Enhanced molecular diagnostics enabling identification of BRCA mutations, HRD status, and FRα expression to guide personalized treatment strategies and improve patient selection for targeted therapies.
• Combination Treatment Strategies: Development of rational drug combinations including PARP inhibitors with bevacizumab, checkpoint inhibitors with chemotherapy, and dual-targeted approaches to overcome resistance mechanisms and extend survival.
• Platinum-Resistant Disease Focus: Intensified research efforts addressing the significant unmet need in platinum-resistant ovarian cancer, with multiple novel agents demonstrating activity after relapse on first-line platinum therapies.

Ovarian Cancer Epidemiology

The report on Ovarian Cancer epidemiology provides a comprehensive analysis of the disease's prevalence, incidence, and patient demographics across the 7MM. It includes age-specific distribution showing that more than 48% of cases occur in women aged 65 and older, with the highest incidence rates observed in the 75-79 age group.

Ovarian Cancer Epidemiology Segmentation

The Ovarian Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total incident cases of ovarian cancer
• Age-specific cases of ovarian cancer
• Type-specific cases of ovarian cancer
• Stage-specific cases of HGSOC and LGSOC
• Biomarker-specific cases of HGSOC and LGSOC

Download the report to understand which factors are driving Ovarian Cancer epidemiology trends @ Ovarian Cancer Epidemiology Forecast

Recent Developments In The Ovarian Cancer Treatment Landscape

• April 2025: Full FDA approval of mirvetuximab soravtansine-gynx (Elahere) for advanced, platinum-resistant ovarian cancer whose tumors overproduce FR-α. The approval followed positive results from the MIRASOL clinical trial showing improved overall survival and progression-free survival compared to standard chemotherapy.​
• June 2025: The FDA granted fast track designation to PHST001, an investigational anti-CD24 monoclonal antibody from Pheast Therapeutics, for advanced platinum-resistant or platinum-sensitive ovarian cancer.
• June 2025: The FDA also granted fast-track designation to CHM CDH17, a novel CAR-T therapy from Chimeric Therapeutics aimed at gastroenteropancreatic neuroendocrine tumors but relevant to solid tumor therapy innovation such as ovarian cancer.
• The FDA approved new agents in ovarian cancer, including antibody-drug conjugates, paving the way for novel therapies in platinum-resistant ovarian cancer in June 2025.
• August 2025: The FDA granted accelerated approval to the combination therapy of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC). This combinational approach targets pathways involved in drug resistance, showing promise for this hard-to-treat subtype.​
• September 2025: The FDA granted Breakthrough Therapy Designation to raludotatug deruxtecan for patients with CDH6-expressing platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers previously treated with bevacizumab.
• In May 2025, the FDA granted accelerated approval to the combination of avutometinib and defactinib (Avmapki Fakzynja Co-pack) for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy. The RAMP-201 trial demonstrated a 44% overall response rate in KRAS-mutated LGSOC patients, with duration of response ranging from 3.3 to 31.1 months.
• In June 2025, dostarlimab-gxly (Jemperli) plus platinum-based chemotherapy followed by maintenance niraparib demonstrated statistically significant improvement in progression-free survival in the phase 3 FIRST/ENGOT-OV44 trial.
• In June 2025, Bio-Thera Solutions announced first patient dosing in a phase 3 clinical trial for BAT8006, an antibody-drug conjugate targeting folate receptor α for platinum-resistant ovarian cancer. Early data presented at ASCO 2025 showed promising results with median PFS of 7.63 months, ORR of 40.7%, and DCR of 80.5% without ocular toxicity or interstitial lung disease.

Ovarian Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ovarian Cancer market or expected to get launched during the study period. The analysis covers Ovarian Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Ovarian Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Ovarian Cancer Therapies and Key Companies

• Olaparib (Lynparza): AstraZeneca
• Niraparib (Zejula): GSK
• Rucaparib (Rubraca): Clovis Oncology
• Mirvetuximab soravtansine-gynx (Elahere): AbbVie (ImmunoGen)
• Bevacizumab (Avastin): Roche/Genentech
• Pembrolizumab (Keytruda): Merck
• Dostarlimab-gxly (Jemperli): GSK
• Avutometinib + Defactinib (Avmapki Fakzynja): Verastem
• Rinatabart sesutecan: Genmab (ProfoundBio)
• LY4170156: Eli Lilly (Mablink)
• Torvutatug samrotecan (AZD5335): AstraZeneca
• BAT8006: Bio-Thera Solutions
• Stenoparib: Allarity Therapeutics
• Oregovomab: OncoQuest Pharmaceuticals

To know more about Ovarian Cancer companies working in the treatment market, visit @ Ovarian Cancer Clinical Trials and Therapeutic Assessment

Ovarian Cancer Market Drivers

• Increasing prevalence of ovarian cancer globally
• Growth of targeted therapies and PARP inhibitors for BRCA-mutated and HRD-positive ovarian cancer
• Emergence of antibody-drug conjugates targeting folate receptor alpha showing objective response rates of 40-60% in platinum-resistant disease, addressing a critical unmet need with mirvetuximab soravtansine-gynx, rinatabart sesutecan, and pipeline candidates.
• Advancements in molecular diagnostics and biomarker testing enabling precision medicine approaches through identification of BRCA mutations, HRD status, and FRα expression to guide personalized treatment strategies.
• Rising healthcare expenditure and government initiatives supporting cancer care, particularly in developed markets with well-established healthcare infrastructure facilitating early diagnosis and comprehensive treatment access.
• Development of combination therapies, including PARP inhibitors with bevacizumab, checkpoint inhibitors with chemotherapy, and dual-targeted approaches demonstrating improved patient outcomes and survival rates.
• Expanding awareness and screening programs leading to increased diagnosis rates, though ovarian cancer lacks effective population-wide screening, making symptomatic detection and high-risk surveillance increasingly important.

Ovarian Cancer Market Barriers

• High cost of targeted therapies and PARP inhibitors limiting patient access, with annual treatment costs exceeding USD 100,000 for many novel agents, including olaparib, niraparib, and mirvetuximab soravtansine-gynx.
• Limited efficacy of immunotherapy as monotherapy with checkpoint inhibitors, achieving response rates of only 10-15% in ovarian cancer, significantly lower than other solid tumors, requiring combination strategies.
• Resistance development to platinum-based chemotherapy and PARP inhibitors reducing long-term efficacy, with many patients experiencing disease progression despite initial response to first-line treatment.
• Lack of effective screening programs for early detection in the general population, resulting in approximately 70% of cases being diagnosed at advanced stage III or IV disease with significantly worse prognosis.
• Complex clinical trial designs and lengthy regulatory approval processes delaying market entry of novel therapies, particularly for biomarker-selected populations requiring companion diagnostic development.
• Variability in patient response due to tumor heterogeneity and diverse molecular profiles including BRCA status, HRD status, and FRα expression, necessitating comprehensive biomarker testing infrastructure.
• Side effects and safety concerns associated with advanced therapies including ocular toxicity with FRα-targeted ADCs, hematologic toxicities with PARP inhibitors, and immune-related adverse events with checkpoint inhibitors.

Scope of the Ovarian Cancer Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan]
• Key Ovarian Cancer Companies: AstraZeneca, Merck, GSK, AbbVie (ImmunoGen), Bristol-Myers Squibb, Roche/Genentech, Clovis Oncology, Genmab, Eli Lilly (Mablink), Verastem, Bio-Thera Solutions, Allarity Therapeutics, OncoQuest Pharmaceuticals, and others
• Key Ovarian Cancer Therapies: Olaparib (Lynparza), Niraparib (Zejula), Rucaparib (Rubraca), Mirvetuximab soravtansine-gynx (Elahere), Bevacizumab (Avastin), Pembrolizumab (Keytruda), Dostarlimab-gxly (Jemperli), Avutometinib + Defactinib (Avmapki Fakzynja), Rinatabart sesutecan, LY4170156, Torvutatug samrotecan (AZD5335), BAT8006, Stenoparib, Oregovomab, and others
• Ovarian Cancer Therapeutic Assessment: Ovarian Cancer current marketed and Ovarian Cancer emerging therapies
• Ovarian Cancer Market Dynamics: Ovarian Cancer market drivers and Ovarian Cancer market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Ovarian Cancer Unmet Needs, KOL's views, Analyst's views, Ovarian Cancer Market Access and Reimbursement

Discover more about therapies set to grab major Ovarian Cancer market share @ Ovarian Cancer Treatment Market